Lilly releases Zepbound® (tirzepatide) single-dose vials, …
INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand.
Eli Lilly to sell Zepbound directly to consumers without ... - ABC News
Aug 27, 2024 · Eli Lilly, the maker of Zepbound, announced Tuesday it will begin selling the weight loss drug directly to consumers through the company's direct pharmacy, LillyDirect.
Lilly launches lower-price weight loss drug without injector pen - CNN
Aug 27, 2024 · Starter doses of the weight-loss drug Zepbound are now available in single-dose vials, drug manufacturer Eli Lilly announced Tuesday, a move the company says will “significantly” expand supply...
FDA approves Zepbound® (tirzepatide) as the first and only …
INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 1 Zepbound may help adults with moderate-to-severe ...
Lilly's Zepbound® (tirzepatide) superior to Wegovy® …
Dec 4, 2024 · SURMOUNT-5 compared Zepbound, a dual GIP and GLP-1 receptor agonist, to Wegovy, a mono GLP-1 receptor agonist in adults living with obesity without diabetes. INDIANAPOLIS, Dec. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial.
Zepbound price cut: Eli Lilly lowers cost of weight loss drug - NBC News
Aug 27, 2024 · Drugmaker Eli Lilly is significantly lowering the prices of the two lowest doses of its blockbuster weight loss drug Zepbound, it said Tuesday, in a move to expand access and ease supply ...
FDA approves Eli Lilly’s Zepbound, a weight loss drug ... - NBC News
The FDA has approved Zepbound, an injectable weight loss drug from Eli Lilly that helped people lose up to 52 lbs in 16 months during clinical trials.
At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales …
Jan 15, 2025 · The Lilly metabolic medicines are still tremendous drivers of revenue. The company expects Mounjaro will tally about $3.5 billion in sales for the fourth quarter of 2024 while Zepbound revenue ...
Eli Lilly's Zepbound Whomps Novo Nordisk's Wegovy In First …
Dec 4, 2024 · Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head-to-head study.
Eli Lilly slashes prices of weight-loss drug Zepbound for ... - CBS News
Aug 28, 2024 · Drugmaker Eli Lilly said Tuesday it will sell single-use vials of its weight-loss drug Zepbound at a fraction of the price of its pens, amid skyrocketing demand among Americans for anti-obesity...